One or two intact local summaries. No averaged regimen, patient-specific dose or automatic source preference.
1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.
Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.
The COLCRYS gout source has different dialysis instructions for prophylaxis and flares. Renal/hepatic impairment plus strong CYP3A4 or P-gp inhibition is a contraindication, not merely another dose-reduction row.
What to reconcile: Check interacting medicines and existing prophylaxis; do not substitute LODOCO cardiovascular instructions.
Open this note and its source referencesCheck interacting drugs before using any renal regimen; prophylaxis and acute flare treatment cannot be combined indiscriminately.
Dialysis evidence: A regimen is reported in selected content
For gout prophylaxis, the mirror calls for close monitoring without adjustment in mild/moderate impairment; severe impairment starts at 0.3 mg/day. Dialysis prophylaxis starts at 0.3 mg twice weekly. Acute-flare treatment in severe impairment is not repeated more often than every 2 weeks; dialysis flare treatment is a single 0.6 mg dose, also not repeated within 2 weeks. Consider alternatives for repeated courses. Flare treatment is not recommended in renally impaired patients already receiving COLCRYS prophylaxis. Renal or hepatic impairment with P-gp or strong CYP3A4 inhibitors is contraindicated. These are COLCRYS gout instructions, not LODOCO cardiovascular dosing or a familial Mediterranean fever protocol.
RDM61-rxlist-colchicine-1aa7fc8d28-C1 · Source locator: Dosage and Administration: renal impairment; named precautions
No new official-label card was obtained for this product in v6.1. Earlier source layers, if present, were retained but not rechecked.
This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.
Pinned reference: https://globalrph.com/blogCalcs/renal-dosing-master/compare.php?id=colchicine&s1=RDM61-rxlist-colchicine-1aa7fc8d28&h1=8b987b6055e80ebc7989a4edbca410240cff4d6f7038b27eecc1be7544c94186